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Editing of mouse and human immunoglobulin
genes by CRISPR-Cas9 system
Taek-Chin Cheong1, Mara Compagno1 & Roberto Chiarle1,2
Applications of the CRISPR-Cas9 system to edit the genome have widely expanded to include
DNA gene knock-out, deletions, chromosomal rearrangements, RNA editing and
genome-wide screenings. Here we show the application of CRISPR-Cas9 technology to edit
the mouse and human immunoglobulin (Ig) genes. By delivering Cas9 and guide-RNA
(gRNA) with retro- or lenti-virus to IgMþ mouse B cells and hybridomas, we induce
class-switch recombination (CSR) of the IgH chain to the desired subclass. Similarly, we
induce CSR in all human B cell lines tested with high efficiency to targeted IgH subclass.
Finally, we engineer mouse hybridomas to secrete Fab0 fragments instead of the whole Ig.
Our results indicate that Ig genes in mouse and human cells can be edited to obtain any
desired IgH switching helpful to study the biology of normal and lymphoma B cells. We also
propose applications that could transform the technology of antibody production.
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G
ene rearrangements editing the immunoglobulin (Ig)
genes such as V(D)J recombination and class-switch
recombination (CSR) require the formation of DNA
double-strand breaks (DSBs) as the key initiating step1–3.
In physiological conditions, DSBs are introduced at the Ig genes
by the activity of B-cell-specific enzymes such as recombination-
activating gene 1/2 (RAG1/2) and activation-induced cytidine
deaminase (AID)1–3. During CSR, AID generates DSBs in the Ig
locus by targeting repetitive sequences in the switch (S) regions
that precede each Ig heavy (IgH) coding sequence1–3. Paired
DSBs in the switch regions are then joined by the classical and
alternative non-homologous end-joining (NHEJ) pathways to
generate a switch of the IgH4. This long range joining is thought
to be part of a general mechanism of DNA repair where two DSBs
are joined in cis over long chromosome distances5. Indeed,
efficient CSR can be obtained in absence of AID or S regions after
the introduction of DSBs by site-specific I-SceI endonuclease6.
The bacterial type II clustered regularly interspaced short
palindromic repeat (CRISPR)-Cas9 (CRISPR-associated Protein
9) systems have great potentials for RNA-guided genome editing,
including multiplexing genome engineering, gene targeting by
homologous recombination, regulation of transcription, chromo-
somal translocation formation, high-throughput functional
genomic screens and even RNA editing7–10. We and others
demonstrated that when two DSBs are simultaneously introduced
in a cell in vitro or in vivo by CRISPR-Cas9 activity, a variety of
gene rearrangements are generated, including large deletions (up
to 12Mb), inversions and chromosomal translocations11–14.
Here we show that the CRISPR-Cas9 system can be adapted
to efficiently induce CSR in primary mouse B cells and human
B-cell lines. In addition, this system can be proficiently used to
engineer hybridoma cells to produce monoclonal antibody with a
switched Ig heavy chain or to secrete the immunoglobulin Fab0
fragments only.
Results
CRISPR-Cas9-mediated CSR in mouse B cells. Since CSR is a
DNA deletion induced by two DSBs occurring in the S regions
preceding the IgH constant sequences, we sought to engineer CSR
by CRISPR-Cas9-mediated DNA deletion. We first designed a
system to target the mouse IgH locus. Given that S regions are
highly repetitive, we generated lentiviral vectors expressing Cas9
and guide-RNA (gRNA) targeting the more specific DNA
sequences flanking immediately upstream
(Sm 50 gRNA and Sg1 50 gRNA) or downstream (Sm 30 gRNA and
Sg1 30 gRNA) of the S regions that precede the mouse Cm and Cg1
IgH constant sequences (Fig. 1a and Supplementary Fig. 1a).
Efficiency of selected gRNA sequences was tested by Surveyor
assay (Supplementary Fig. 1b). By introducing simultaneous DSBs
in sites flanking the Sm and Sg1 regions, the prediction was to
generate deletions of the DNA segment encompassed by the two
DSBs as well as excision circles in a process closely mimicking CSR
occurring in B cells3. To test this prediction, we first transduced
immortalized mouse fibroblasts. PCRs with specific primers
confirmed that the expected deletions were obtained with all
four gRNA combinations (Fig. 1a). Sanger sequencing of PCR
products demonstrated not only the expected DNA junctions with
a predominance of precise junctions between the Cas9-mediated
DSBs, but also 50 or 30 deletions and insertions, as previously
described11–14 (Fig. 1b). PCR also detected the expected excision
circles as well as inversions of the DNA segment encompassed by
the DSBs, as we previously demonstrated in a different model13
(Supplementary Fig. 2a,b).
Next we sought to induce CSR in primary mouse B cells. When
activated in vitro by anti-CD40 antibody and Interleukin-4 (IL-4),
mouse B cells typically are induced to high levels of CSR
(Supplementary Fig. 3c)15, impairing a precise assessment of CSR
induced by the CRISPR-Cas9 system. Thus, we decided to exploit
AID-deficient B cells in which CSR is practically undetectable15.
Since retroviruses are more efficient to transduce primary B cells
than lentiviruses, we generated a retroviral vector that expressed
Cas9 and the same gRNAs used in fibroblasts (Supplementary
Fig. 3a,b). Remarkably, with all four Cas9–gRNA combinations,
we observed a small but distinct population of AID-deficient B
cells that switched from IgM to IgG1 (Fig. 1c; Supplementary
Fig. 3d). The overall frequency of 1% CSR was in line with
previous reports describing chromosomal translocations induced
by CRISPR-Cas9 (refs 11–14).
CRISPR-Cas9-mediated CSR in mouse hybridoma cells. To
further validate the efficiency of the CRISPR-Cas9 system to
induce CSR in mouse cells, we transduced IgMþ hybridoma cells.
Surprisingly, higher levels of CSR than in primary B cells were
observed in all hybridomas tested with all gRNA combinations
(range 4–11%; Fig. 1d,e). Remarkably, similar levels of CSR were
observed when the entire Sm and Sg1 regions were conserved
(Sm 30 gRNA with Sg1 50 gRNA) or deleted (Sm 50 gRNA with Sg1
30 gRNA; Fig. 1a,d,e). By single-cell cloning, we isolated pure IgG1
hybridomas at the expected frequency (12 pure IgG1 clones out of
189 total clones: 6.3%; Supplementary Fig. 4). Overall, these
results from primary mouse B cells and hybridomas showed that
CSR can be achieved at high frequency by CRISPR-Cas9 system,
and that hybridoma can be engineered to switch to the desired
IgH subclass. Importantly, according to our strategy, CSR-edited
hybridoma will retain the same V(D)J-coding sequence (Fig. 1a).
Thus, this technology could be readily used to generate
hybridoma with the same antigen specificity but different
IgH subclass. This would represent an important application
for antibody production because different IgH subclasses
(for example, IgG1 versus IgG4) are known to have different
affinity for the Fc receptor, potency in complement activation,
biological properties in terms of half-life and tissue diffusion, as
well different biochemical properties16.
CRISPR-Cas9-mediated CSR in human B cells. To investigate
whether engineering of CSR could be efficiently achieved also in
human B cells, we designed Cas9–gRNA lentiviral vectors to
target the regions flanking the human Sm (Sm 50 gRNA and
Sm 30 gRNA), Sg3 (Sg3 30 gRNA), Sg1 (Sg1 30 gRNA) and Sa1
(Sa1 30 gRNA) regions (Fig. 2a). We selected a panel of IgMþ
human lymphoma cell lines that included mantle cell lymphoma
(JEKO-1, GRANTA-519, UPN-1, UPN-2, MAVER-1, MINO and
Z138), Burkitt lymphoma (BL-41 and BJAB) and chronic
lymphocytic leukaemia (MEC-1). As shown in mouse B cells,
deletion junctions were readily identified in all combinations
tested and Sanger sequencing confirmed a prevalence of direct
junctions over deletions and insertions (Fig. 2b; Supplementary
Fig. 5). Excision circles and inversions were detected as well
(Supplementary Figs 6 and 7). Remarkably, high levels of
CSR were observed in each cell line tested ranging from 1%
(MINO) to 60% (JEKO-1), with an average of 10% (Figs 2c
and 3). The only lentivirus that did not induce CSR was Sm 50
gRNA in Z138 cell line. When we sequenced the DNA of Z138
corresponding to the gRNA target region, we found a small
deletion encompassing the Sm 50 gRNA-targeted site, thus
explaining why this gRNA combination failed to induce CSR.
When we transduced B lymphoma cells with three gRNAs
targeting the flanking regions of Sm, Sg1 and Sa, we
simultaneously obtained IgG1þ and IgAþ cells from the original
IgMþ cells at comparable frequency (Supplementary Fig. 8).
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Next, we investigated whether human B cells could be
engineered to undergo consecutive rounds of CSR, that is,
whether B cells induced to switch first from IgM to IgG3 (or IgG1)
were then editable to a sequential switch to IgA. Starting from
IgMþ JEKO-1 cells, we first induced CSR to IgG3 or IgG1 by
lentiviral transduction with Sm 30 gRNA and Sg3 30 gRNA or Sg1
30 gRNA and isolated pure IgG3þ or IgG1þ clones (Fig. 2d and
Supplementary Fig. 9). Next, we transduced IgG3þ or IgG1þ
clones with Sm 50 gRNA and Sa1 30 gRNA to generate new DSBs
in regions flanking Sm and Sa. Remarkably, we obtained high
levels of CSR to IgA, indicating that human B cells can be
engineered to undergo multiple rounds of CSR at the same
efficiency rate (Fig. 2d and Supplementary Fig. 9).
The high efficiency of CSR obtained in human B cell allows for
potential studies on the biological role of different IgH subclass in
lymphoma biology. Signalling through the B cell receptor (BCR)
is required to sustain survival and proliferation of normal B
cells17,18, and drugs inhibiting the BCR signalling are effective in
the treatment of B cell lymphoma19. However, it is not clear
whether different IgH subclasses that recognize the same antigen
can affect lymphoma growth, possibly through a different potency
or quality of the BCR signalling. The efficiency and rapidity of our
CRISPR-Cas9-based method for CSR opens the possibility to
address these questions. As a proof of principle, we followed over
time B lymphoma cells engineered to switch to different IgH
subclasses. First, a small fraction of lymphoma cells transduced
with Cas9–gRNA lost the expression of any IgH, likely due to
large deletions around the Cas9 cleavage site or to non-coding
inversions or translocations. These IgH-negative cells were
selectively depleted over time, indicating a growth disadvantage
of B lymphoma cells that lost the BCR signalling, as expected by
previous studies17,18 (Fig. 4a-d). More surprisingly, different
subclasses of IgH had contrasting biological effects on lymphoma
growth, as IgG1þ cells had a significant growth disadvantage over
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Figure 1 | Induction of class-switch recombination (CSR) by CRISPR-Cas9 system in mouse cells. (a) Top: genomic organization of the mouse IgH
constant region locus and position of the gRNAs used in this study. Bottom: schematic representation of four possible CSR products induced by deletion of
DNA segments between Sm and Sg1 regions. Black arrows indicate the PCR primers designed to sequence the deletions. Gels show PCR amplicons obtained
with the indicated primers. (b) An example chromatogram showing a perfect Sm 50 and Sg1 30 genomic junction, as well as representative sequences of
junctions identified from 30 clones. Ref. Seq., sequence of the predicted genomic junction between Sm 50 and Sg1 30 regions. Green: insertions; Dashes:
deleted bases. (c) Mouse B cells isolated from the spleen of 129S2 WTand AID-deficient mice were activated by anti-CD40 antibody and IL-4 for 1 day and
then transduced with retrovirus expressing Cas9 nuclease and gRNAs used in (a). Empty GFP- or AID- expressing retroviruses were used as negative or
positive controls, respectively. At day 4, cells were collected, stained with IgG1 antibody, and then analysed by flow cytometry. IgG1
þ cells were gated on
GFP-positive population. Mean±s.d.; n¼ 3 biological replicates for each condition. Statistical analysis determined using unpaired t-test (**Po0.01;
***Po0.001). (d,e) IgMþ hybridomas were transduced with four different combinations of lentiviruses expressing Cas9 nuclease and gRNAs as above.
Representative zebra plots (d) and average percentages±s.d. of CSR (e) from six independent experiments are presented.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10934 ARTICLE
NATURE COMMUNICATIONS | 7:10934 | DOI: 10.1038/ncomms10934 | www.nature.com/naturecommunications 3
IgMþ cells, whereas IgG3þ or IgAþ cells were positively selected
(Fig. 4a-d), thus indicating that different IgH subclasses in B cell
lymphoma have different biological properties.
Next, we further investigated whether loss of BCR signalling
the lead to growth disadvantage in IgH-negative cells could be
rescued by compensatory activation of key pathways downstream
of the BCR signalling. This is an important biological concept
because the BCR signalling is essential for the survival of
malignant B cells through the activation of key downstream
molecules such as the PI3Kd pathway18. To this end, we took
advantage of a newly discovered point mutation (PI3KdE1021K)
that constitutively activates PI3Kd independently of upstream
BCR signalling and was recently described in patients
with immunodeficiency and impaired CSR20,21. After induction
of IgH loss in the JEKO-1 cell line by transduction with either
Sm 50/Sg3 30 or Sm 30/Sg3 30 gRNAs, we subsequently transduced
the lymphoma cells with lentivirus expressing GFP as reporter
(control vector) or GFP and PI3KdE1021K. IgH-negative
lymphoma expressing GFP were progressively depleted with
similar kinetics to untransduced cells. In contrast, IgH-negative
lymphoma cells expressing PI3KdE1021K were significantly
rescued as compared to GFP- or GFPþ control cells (Fig. 4e).
Generation of Fab0 fragment-secreting hybridomas. Finally, the
high efficiency of CRISPR-Cas9 system to edit the IgH locus
prompted us to further investigate possible applications in anti-
body production. For several experimental or clinical applica-
tions, Fab0 fragments are preferable to whole antibodies. To
obtain Fab0 fragments, purified antibodies are often processed by
enzymatic digestion with proteases, such as papain or pepsin,
followed by further purification to remove the Fc binding portion
Human IgH locus 14q32
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Figure 2 | Induction of CSR by CRISPR-Cas9 system in human B cell lines. (a) Top: genomic organization of the human IgH constant region locus and
position of the gRNAs. Bottom: schematic representation of six possible CSR products induced by deletions between Sm and Sg3, Sg1 or Sa1 regions. Black
arrows indicate the PCR primers designed to detect deletion. Gels show PCR amplicons obtained with the indicated primers. (b) Representative sequences
of junctions identified from 30 clones for Sm 30 and Sg1 30 genomic region. Ref. Seq., sequence of the predicted genomic junction between Sm 30 and Sg1 30
region. Dashes: deleted bases. (c) IgMþ JEKO-1 cells were transduced with lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm and Sg3, Sg1 or
Sa1 flanking regions. Cells were collected, co-stained with antibodies against CD19 and IgG or IgA, and analysed by flow cytometry. Representative zebra
plots from three independent experiments are presented. Percentages of events are indicated in the corresponding quadrants. (d) To induce sequential CSR
from IgM to IgG and then to IgA, IgMþ JEKO-1 cells were transduced with lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm 30 and Sg3 30
flanking regions to generate IgG3þ JEKO-1 cells. IgG3þ cells were transduced again with lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm 50
and Sa1 30 flanking regions. Four days later, cells were collected, co-stained with IgM, IgG, or IgA antibodies and analysed by flow cytometry. Representative
zebra plots from three independent experiments are presented. Percentages of events are indicated in the corresponding quadrants.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10934
4 NATURE COMMUNICATIONS | 7:10934 | DOI: 10.1038/ncomms10934 | www.nature.com/naturecommunications
and to maintain the antigen-specific binding portion (Fab0 frag-
ment)22. We reasoned that we could produce Fab0 fragments
directly in hybridoma cells by deleting the Fc-coding sequence of
the IgH chain. To obtain the Fc portion deletion, we designed
gRNAs targeting the DNA proximal to the papain cleavage site of
the IgG1 coding sequence. We tested either a frameshift approach
where the deletion of the Fc portion is achieved by an out-of-
frame NHEJ-mediated repair of the DSB introduced by Cas9 (Fc
50) or a complete deletion approach where the DNA sequence for
the Fc portion is deleted by two flanking DSBs (Fc 50 and Fc 30)
(Fig. 5a). As a consequence of this deletion, the hybridoma should
become IgH-negative because of the loss of the IgH membrane-
binding domain23. Indeed, by either approach, we observed a
high percentage of IgG1-negative cells (Fig. 5b,c), likely indicating
an efficient deletion of the Fc fragment. To compare the relative
efficiency of the two approaches we isolated single clones from a
hybridoma co-transduced with Fc 50 and Fc 30. Out of the 64
isolated single-cell clones, only 4 (6.2%) deleted the Fc-coding
sequence of the IgH chain, whereas in the majority of the clones
the loss of the Fc coding was mediated by frameshift
(Supplementary Figs 10 and 11). Next, we expanded IgG1-
negative clones (Supplementary Fig. 12) and tested for production
of Fab0 fragments. We collected hybridoma supernatants and
separated the proteins on a SDS–PAGE gel in non-reducing
conditions. By western blot assay with an anti-kappa-light chain
antibody, IgG1-negative engineered hybridomas secreted Fab0
fragments together with the expected kappa-light chain24,
whereas control IgG1þ hybridomas secreted the whole IgG1 as
expected (Fig. 5d,e). As predicted, both the Fab0 fragments and
the whole IgG1 completely disappeared when the SDS–PAGE gel
was run in reducing conditions (Supplementary Fig. 13). Thus,
hybridomas producing Fab0 fragments can be generated rapidly
and effectively by CRISPR-Cas9 technology.
Discussion
Altogether our data demonstrate the feasibility of a fast and
efficient editing the Ig genes in human and mouse B cells by
CRISPR-Cas9 technology. CSR was induced with equal efficiency
whether the gRNAs were directed to target sequences upstream or
downstream the switch regions, as predicted by the current
models of CSR1,25. Consistent with the notion that CSR is a
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Figure 3 | CSR in a panel of human B-cell lymphoma lines. Ten different human B-cell lymphoma lines (JEKO-1, GRANTA-519, UPN-1, UPN-2, MAVER-1,
MINO, Z-138, BL-41, BJAB and MEC-1) were transduced with lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm and Sg3, Sg1, or Sa1 flanking
regions. Two days later, cell lines were selected with puromycin (0.2mgml 1) for 3 days. Live cells were collected, co-stained with CD19 and IgG or IgA
antibodies, and analysed by flow cytometry. As a control, non-transduced or single lentivirus-transduced cells were used. Data were analysed by FlowJo
software. Mean±s.d.; n¼ 3 biological replicates for each condition.
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peculiar form of gene rearrangement in the IgH locus, when we
introduced two gRNAs in the cells we found additional genomic
rearrangements, such as inversions and interchromosomal
translocations as we and others previously described with
CRISPR-Cas9 technology11–14. The predominance of precise
junctions between the two DSBs generated by Cas9 reflects the
described property of Cas9 to generate blunt ends 3 bp upstream
of the PAM sequence26. Blunt ends are then joined by the
c-NHEJ pathway, which could also be responsible for small
deletions or insertions4.
Efficiency of CSR was remarkably high in hybridoma and human
B lymphoma cells. This was quite surprising but consistent with the
observations made by our group and others that rearrangements
occur with high frequency between two DSBs that occur at a low
genomic distance on the same chromosome5,15,27,28. The lower CSR
achieved in primary mouse B cells was likely due to a lower
efficiency of transduction than hybridomas and human B cells.
Currently used lentiviral or retroviral CRISPR-Cas9 vectors produce
relatively low viral titres due to the large size of the constructs29. The
recent demonstration that smaller Cas9 molecules obtained by
Staphylococcus aureus have similar efficiency to Streptococcus
pyogenes (SpCas9) allows the design of smaller retroviral
constructs that should generate more efficient viruses30. In
addition, the cloning of two gRNAs in the same vector instead of
two independent vectors should further increase the efficiency of
CSR by increasing the number of cells co-expressing the two gRNAs.
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Figure 4 | Biological effects of IgH subclass switch in human lymphoma cell growth. (a–c) To understand the growth of B cells after switch of the IgH
subclass, JEKO-1 cells were co-transduced with two lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm, Sg3 30 (a), Sg1 30 (b) and Sa1 30
(c) flanking regions. Cells were co-stained with antibodies against IgM and IgG or IgA and analysed by flow cytometry over time. (d) Statistical analysis of
relative growth rates from lymphoma cells from Fig. 4a–c. Data are from at least four experiments in each condition. P values are calculated for each IgH
subclass compared with native IgMþ cells. Data are expressed as mean±s.d. for four independent experiments. Statistical analysis determined using two-
way ANOVA (**Po0.01; ***Po0.001). (e) JEKO-1 cells were transduced with lentiviruses expressing Cas9 nuclease and gRNAs targeting Sm and Sg 3
regions. After 5 days, cells were transduced with retroviral vector expressing PI3KdE1021K or control vector. Cells were co-stained with antibodies against
IgM and IgG to allow the gating on the IgH-negative population (IgH ¼ IgM/IgG ) and percentages of GFPþ cells were analysed over time by flow
cytometry. As additional control IgH- cells not transduced with the retrovirus (GFP) were analysed. Data are from two independent experiments each
repeated in duplicates and are expressed as mean±s.d. Statistical analysis determined using two-way ANOVA (***Po0.001).
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CRISPR-Cas9-mediated CSR in hybridoma cells was efficient,
fast and easy allowing for CSR to any desired IgH subclass.
Implication for the technology of antibody production could be
profound. For example, IgG antibodies are preferred for
applications such as western blot analysis, immunohistochemistry
and ELISA, whereas IgM clones are typically discarded because
IgM are pentameric, more difficult to purify and less stable than
IgG. In addition, different IgG subclasses have different stability,
as well as biological and biochemical properties. For examples,
effector functions in terms of triggering FcgR-expressing cells,
activating complement, phagocytosis or antibody-dependent
cell-mediated cytotoxicity are different within IgG1, IgG2, IgG3
and IgG4 subclasses30. By applying the approach we propose,
it would be possible to easily switch hybridomas to the desired
IgH subclass for any laboratory or therapeutic use. In addition,
we have also shown that hybridoma can be engineered to
produce Fab0 fragments instead of the corresponding whole
IgH molecule. Fab0 fragments were directly produced and
secreted by hybridoma cells in culture at comparable levels to
the unedited whole IgH molecules. This approach would
largely simplify the method for the production of Fab0
fragments that is currently based on several steps of protease
cleavage followed by purification of the resulting fragments. We
propose that engineering hybridomas to directly produce Fab0
fragments will represent an important advancement given that
Fab0 fragments are preferred for several experimental approaches
as well as for therapeutic deliver of more effective antibody–drug
conjugates31.
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Figure 5 | Generation of Fab0 fragments by CRISPR-Cas9 system in mouse hybridomas. (a) Top: schematic representation of mouse IgG antibody and
target sites of two different gRNAs used for Fab0 fragment production. By using lentiviruses expressing Cas9 nuclease and Fc 50 or Fc 50/Fc 30 guide RNAs,
Fab0 fragments were produced by frameshift (left) or deletion (right) of the IgH Fc fragment, respectively. Bottom: schematic depiction of 50 gRNA
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þ hybridomas were transduced with lentivirus
expressing Cas9 nuclease and gRNAs targeting Fc 50 or Fc 50 and Fc30 regions. gRNAs targeting Sm 50, Sg1 30 or Fc 30 were used as negative controls.
Hybridomas were selected with puromycin, stained with IgM and IgG1 antibodies, and analysed by flow cytometry. Representative zebra plots from three
different IgG1
þ hybridomas are presented. Percentages of events are indicated in the corresponding quadrants. (c) Histograms representing the
percentages of IgG-negative cells are shown with mean±s.d.; n¼ 3 biological replicates for each condition. Statistical analysis determined using unpaired
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shown. Supernatants were loaded on a SDS–PAGE in non-reducing condition, and developed with an anti-mouse kappa-light chain antibody. Three different
IgG1
þ hybridomas were used as controls.
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Finally, CSR was achieved in human B cells at high efficiency, a
feat never accomplished so far. In contrast to primary mouse B
cells, induction of CSR in human B cells is largely inefficient with
current methods32. In contrast, by CRISPR-Cas9 technology we
were able to rapidly and efficiently induce CSR in all human B-cell
lines tested to any desired IgH subclass. We propose that Cas9-
mediated editing provides a highly useful approach for the study of
the functional activity of different IgH subclass in the physiology
and pathology of human B cells as the contribution of the different
IgH subclasses is largely unknown. Furthermore, unveiling the
network of signalling pathways initiated by the BCR has become
increasingly important to understand the physiology of normal B
cells17 as well as the pathological survival and expansion of
neoplastic B cells19. Indeed, inhibition of BCR activity has recently
changed the treatment landscape for B-cell malignancies33–38.
Inhibitors of key molecules in BCR signalling such as PI3Kd
inhibitors (idelalisib) or Bruton tyrosine kinase-BTK inhibitors
(ibrutinib) have been recently approved by the FDA for the
treatment of CLL or MCL39 and others are under investigation40.
As we showed in reconstitution experiments with activated PI3Kd
constructs, modelling CSR or eliminating BCR signalling by
CRISPR-Cas9 technology will provide opportunities to precisely
reconstruct the contribution of single pathways or molecules to the
biology of normal and neoplastic B cells.
Methods
Animals. Female 129/SvJ, 129S2 and AID-deficient mice at 8-12 weeks of age were
used in the experiments. A minimum of three mice for each experiment was used.
No exclusion criteria were used. 129S2 mice (Charles River) and AID-deficient
mice, which were kindly provided by Dr Frederick W. Alt (Boston Children’s
Hospital), were housed and maintained in the specific pathogen free (SPF) facility
at Boston Children’s Hospital. Animal experiments were performed under protocol
approved by the Institutional Animal Care and Use Committee (IACUC) of Boston
Children’s Hospital (Protocol #13-01-2295).
Plasmid DNA constructions. For SpCas9 expression and generation of
guide-RNA (gRNA), the 20-nucleotide target sequences were selected to precede a
50-NGG protospacer-adjacent motif (PAM) sequence. To minimize off-target
effects, the CRISPR design tool from Dr Feng Zhang laboratory was used
(http://crispr.mit.edu/). All gRNA and PAM sequences used in this study are listed
in Supplementary Table 1. Oligonucleotides were purchased from Integrated DNA
technology (IDT), annealed and cloned into the BsmBI–BsmBI sites downstream
from the human U6 promoter in LentiCRISPR v2 plasmid, which was a gift from
Dr Feng Zhang (Addgene plasmid #52961). Oligonucleotides used in this study for
cloning are listed in Supplementary Table 2.
To generate RetroCRISPR v1 plasmid, all gRNAs were first cloned in
LentiCRISPR v2 vector. To obtain retroviral backbone, pMSCVgfp::AID plasmid, a
gift from Nina Papavasiliou (Addgene plasmid # 15925), was digested with XhoI
and EcoRI restriction enzymes to remove AID gene, and repaired by Klenow
fragment. The constructs harbouring the U6 promoter–gRNA–gRNA scaffold-
EF1a promoter-SpCas9-NLS-flag-P2A-Puro were obtained from LentiCRISPR v2
vector, and repaired by Klenow fragment. By ligating those two constructs, we
generated RetroCRISPR v1 plasmid (Supplementary Fig. 3a). Since smaller size of
plasmid is more efficient to produce retroviral particles, we decided to make a
RetroCRISPR v2 plasmid. The construct harbouring BamHI-P2A-GFP-ClaI was
PCR amplified using pMSCVgfp:AID as a template with forward primer: 50-TAA
GGGATCCGGCGCAACAAACTTCTCTCTGCTGAAACAAGCCGGAGATGT
CGAAGAGAATCCTGGA CCGGTGAGCAAGGGCGAGGAGCTGTTC-30 and
reverse primer: 50-TAAGATCGATGGCCGCTTTACTTGTACAGCTCGTCC
ATGC-30 (BamHI and ClaI sites are underlined). To generate RetroCRISPR v2
plasmid, PCR products were cloned into RetroCRISPR v1 plasmid digested with
BamHI and ClaI restriction enzymes (Supplementary Fig. 3b).
PI3KdE1021K construct cloned in GFP-reporter MIGR1 retroviral vector was a
kind gift from Dr Klaus Okkenhaug (The Babraham Institute, Cambridge, UK). As
a control, we used GFP-reporter MIGR1 plasmid, which was a gift from Warren
Pear (Addgene plasmid # 27490).
Lenti- and Retro-viral particle productions. HEK293FT cells (Invitrogen),
Phoenix-ECO cells (ATCC), and GP2-293 packaging cells (Clontech) were main-
tained in DMEM supplemented with 10% fetal bovine serum (FBS; ATLANTA),
100 units per ml penicillin–streptomycin (P/S; Corning), and 2mM L-Glutamine
(L-Glu; Corning). Cells were cultured at 37 C in 5% CO2 atmosphere. The cell lines
were tested and resulted negative for Mycoplasma contamination.
To generate lentiviral particle, 5.5 106 HEK293FT cells were plated per 10-cm
dish. The following day, cells were transfected by calcium phosphate transfection
method (CalPhos Mammalian Transfection Kit; Clontech) with 7.2 mg of
lentiCRISPR plasmid, 3.6 mg of pMD2.G (Addgene plasmid #12259), 3.6 mg of
pRSV-Rev (Addgene plasmid #12253) and 3.6 mg of pMDLg/pRRE (Addgene
plasmid #12251). The media was changed 8 h post-transfection. The viral
supernatant was collected 48 h post-transfection, passed through a 0.45-mm filter,
pooled and used either fresh or snap frozen.
To generate retroviral particle for mouse B cells, 3.5 106 Phoenix-ECO cells
were plated per 10-cm dish. The following day, cells were transfected by calcium
phosphate transfection method (CalPhos Mammalian Transfection Kit) with 10 mg
of retroviral plasmid and 5 mg of pCL-Eco retrovirus packaging plasmid. The media
was changed 8 h post-transfection. The viral supernatant was collected 48 h
post-transfection, passed through a 0.45-mm filter, pooled and used either fresh or
snap frozen.
To generate retroviral particle for human cells, 3.5 106 GP2-293 packaging
cells were plated per 10-cm dish. The following day, cells were transfected by Xfect
transfection reagent (Clontech) with 10 mg of retroviral plasmid and 5 mg of
pCMV-VSV-G (Addgene plasmid #8454) retrovirus envelop plasmid. The media
was changed 4 h post-transfection. The viral supernatant was collected 48 h
post-transfection, passed through a 0.45-mm filter, pooled and used either fresh or
snap frozen.
Cell cultures, transduction and puromycin selection. Mouse fibroblast cells
immortalized with SV-40 LT (pBABE-puro SV40 LT; Addgene plasmid # 13970)
were maintained in DMEM supplemented with 10% FBS, 100 units per ml P/S, and
2mM L-Glu. Cells were cultured at 37 C in 5% CO2 atmosphere. For transduction,
2 104 cells were plated into six-well plates. The following day, cells were trans-
duced with viral supernatant supplemented with 6 mgml 1 polybrene. The viral
supernatant was exchanged for fresh medium 6 h later. After 2 days, cells were
treated with 6 mgml 1 of puromycin to select resistant cells until non-infected cells
were completely dead.
Naive B cells were separated from total spleen cell suspensions using anti-CD43
magnetic microbeads (Miltenyi). The CD43-negative fraction was cultured with
anti-CD40 antibody (1 mgml 1; eBioscience) and IL-4 (20 ngml 1; PeproTech)
for 4 days. Retrovirus infection was performed 24 h post-activation. Activated-B
cells were transduced with viral supernatant supplemented with 6 mgml 1
polybrene. The viral supernatant was exchanged for fresh medium containing
anti-CD40 antibody and IL-4 6 h later.
Hybridomas were generated by fusion between anti-CD40 and IL-4-stimulated B
cells from 129/SvJ mice and NS-1 fusion partner myeloma cells on day 4 and were
recovered after 7 days selection with 1 Hypoxanthine Aminopterin Thymidine
(HAT) medium. Single clones from each well were picked and screened by ELISA on
their supernatants with IgM and IgG1 capturing and revealing antibodies (Southern
Biotech). Only clones that were single positive for one of the two antibody classes
were used in this study. Hybridomas were cultured in RPMI 1640 medium
GlutaMax (Invitrogen) supplemented with 15% FBS and 100 units per ml P/S.
Hybridomas were maintained at 37 C in 5% CO2 atmosphere. For transduction,
2 105 cells were plated into six-well plates and transduced with viral supernatant
supplemented with 6mgml 1 polybrene. The viral supernatant was exchanged for
fresh medium 6h later. After 2 days, cells were treated with 3mgml 1 of puromycin
to select resistant cells until non-infected cells were completely dead.
Mantle cell lymphoma (JEKO-1, GRANTA-519, MAVER-1 and MINO from
DSMZ; Z-138 from ATCC; UPN-1 and UPN-2 from Dr Alberto Zamo’
(University of Verona, Italy), Burkitt lymphoma (BL-41 and BJAB from DSMZ),
and chronic lymphocytic leukaemia (MEC-1 from DSMZ) cell lines were used in
this study. All human lymphomas were cultured and maintained in RPMI 1640
medium supplemented with 10% FBS, 100 units per ml 1 P/S, and 2mM L-Glu.
All cell lines were cultured at 37 C in 5% CO2 atmosphere. The cell lines all tested
negative for Mycoplasma contamination. For transduction, 2 105 cells were
plated into six-well plates and transduced with viral supernatant supplemented
with 6 mgml 1 polybrene. The viral supernatant was exchanged for fresh medium
6 h later. After 2 days, cell lines were treated with 0.2 mgml 1 of puromycin to
select resistant cells until non-infected cells were completely dead. For PI3KdE1021K
rescue experiments, JEKO-1 cells were first transduced with lentiviruses to induce
deletion between Sm and Sg3, cultivated for 5 days and then transduced with
GFP-reporter PI3KdE1021K or control MIGR1 retrovirus.
Genomic DNA isolation, PCR and sequencing analysis. Mouse fibroblast,
hybridomas and JEKO-1 cells were transduced with lentiviruses, selected with
puromycin and collected after 5 days of transduction. Genomic DNA was extracted
using Rapid lysis buffer (100mM Tris-HCl pH8.0, 200mM NaCl, 5mM EDTA,
0.2% SDS) with 100 mgml 1 Proteinase K by incubating at 56 C overnight.
Genomic DNA was precipitated in one volume isopropanol, and the DNA pellet
was resuspended in 10mM Tris-HCl (pH 8.0). Primers used for PCR amplifica-
tions to detect deletions, inversions, and excision circles from mouse fibroblasts,
hybrodomas or JEKO-1 cells are listed in Supplementary Table 3. PCR products
were gel purified and cloned using pGEM-T easy vector system (Promega).
Mutations were identified by Sanger sequencing. Uncropped gel images are shown
in Supplementary Figs 14 and 15.
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Surveyor assay. The genomic region flanking the CRISPR target sites was PCR
amplified (Surveyor primers are listed in Supplementary Table 3), and products were
purified using PCR purification kit (QIAGEN) following the manufacturer’s protocol.
A total of 400 ng of the purified PCR products were mixed with 2ml 10 Taq DNA
Polymerase PCR buffer (Life Technologies) and ultrapure water to a final volume of
20ml, and subjected to a reannealing process to enable heteroduplex formation: 95 C
for 10min, 95 C to 85 C ramping at  2 C per second, 85 C to 25 C at  0.25 C
per second, and 25 C hold for 1min. After reannealing, products were treated with
SURVEYOR nuclease and SURVEYOR enhancer S (Transgenomics) for 1 h at 42 C,
and analysed on 2% high-resolution agarose gel (A4718, Sigma Aldrich). Gels were
stained with ethidium bromide (Sigma Aldrich) and imaged with a Gel Doc gel
imaging system (Bio-rad). Quantification was based on relative band intensities. Indel
percentage was determined by the formula, 100 (1 (1 (bþ c)/(aþ bþ c))1/2),
where a is the integrated intensity of the undigested PCR product, and b and c are the
integrated intensities of each cleavage products.
Flow cytometry. Mouse B cells and hybridomas were stained with PE-conjugated
anti-IgG1 antibody (Clone A85-1, 550083, BD Pharmingen, 1:100 dilution) or
APC-conjugated anti-IgM antibody (17-5790-82, eBioscience, 1:100 dilution) for
30min on ice, and analysed using a FACSVerse flow cytometer (BD Biosciences).
IgG1þ cells were gated on GFP. Data were analysed by FlowJo software.
Human lymphoma cells were co-stained with APC-conjugated anti-CD19
(Clone 4G7-2E3, FAB4867A, R&D System, 1:100 dilution) and either FITC-
conjugated anti-IgM (AHI1608, MyBioSource, 1:100 dilution) or FITC-conjugated
anti-IgG (AHI1308, MyBioSource, 1:100 dilution) or FITC-conjugated anti-IgA
antibodies (AHI1108, MyBioSource, 1:100 dilution) for 30min on ice to detect IgG
or IgA switching, respectively. For simultaneous switching, JEKO-1 cells were
transduced with three different lentiviruses indicated in Supplementary Fig. 9. Cells
were co-stained with PE-conjugated anti-IgG (AHI1307, MyBioSource) and FITC-
conjugated anti-IgA antibodies (MyBioSource) for 30min on ice. To detect
sequential switching, cells were stained with the three following combinations:
FITC-conjugated anti-IgM and PE-conjugated anti-IgG, FITC-conjugated anti-IgA
and PE-conjugated anti-IgG, or PE-conjugated anti-IgM (AHI1607, MyBioScience,
1:100 dilution) and FITC-conjugated anti-IgA antibodies for 30min on ice. Cells
were analysed using a FACSVerse flow cytometer (BD biosciences). Data were
analysed by FlowJo software (FlowJo).
Western blot analysis. IgG1- or Fab0 fragment-producing hybridomas were
cultured in six-well plates (3 106 cells in 2ml of HBSS). After 24 h, supernatants
were collected and centrifuged to remove dead cells. For non-reducing condition,
supernatants were mixed with loading buffer without reducing reagents. For
reducing condition, supernatants were mixed with loading buffer containing
b–mercaptoethanol and boiled at 95 C for 5min. In both conditions, samples were
loaded on 4-15% Mini-PROTEIN TGX gels (BIO-RAD), transferred on
nitrocellulose membrane (GE Healthcare), blocked with 5% Skim milk (BIO-RAD),
incubated with Rat monoclonal anti-mouse kappa-light chain (HRP) (clone
H139-52.1, ab99632, Abcam, 1:5,000 dilution) or Goat polyclonal anti-mouse
IgG-H&L chain (HRP) (NA931V, GE Healthcare, 1:5,000 dilution), and developed
with ECL solution (GE Healthcare). Uncropped western blot images are shown in
Supplementary Figs 16 and 17.
Statistical analysis. The statistical analysis represented mean±s.d. from three or
more independent experiments. Data were analysed by unpaired t-test for group
differences and by two-way analysis of variance analysis of variance for condition
and group differences together using GraphPad Prism 6 software; **Po0.01,
***Po0.001.
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